ARQT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Arcutis Biotherapeutics Inc (ARQT) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown strong revenue growth and positive analyst sentiment, the technical indicators are neutral to slightly bearish, and the lack of recent news or significant trading trends suggests no immediate catalyst for a price surge. The investor might consider holding off for a clearer entry point.
The MACD is negatively expanding below 0, indicating bearish momentum. RSI is at 33.642, which is neutral but leaning towards oversold territory. Moving averages are converging, showing no clear trend. The stock is trading near its S1 support level of 23.534, with resistance at 25.807. Overall, the technical indicators suggest a neutral to slightly bearish trend.
Strong revenue growth in Q4 2025, up 81.48% YoY. Analysts have raised price targets and maintained positive ratings, citing strong commercialization efforts and increased guidance. Gross margin improved slightly to 90.97%.
Net income and EPS have significantly declined YoY, with net income dropping -261.24% and EPS down -255.56%. MACD and RSI indicate bearish momentum. No recent news or significant trading trends from hedge funds or insiders. No recent congress trading data.
In Q4 2025, revenue increased by 81.48% YoY to $129.5 million, but net income dropped significantly by -261.24% YoY to $17.4 million. EPS also fell by -255.56% YoY to $0.14. Gross margin improved slightly to 90.97%.
Analysts are positive on ARQT, with multiple firms raising price targets to $34-$35 and maintaining Buy or Outperform ratings. They cite strong Q4 results, increased guidance, and successful commercialization efforts as reasons for their optimism.
